EC 231-493-2
Also known as betadex and Cavamax W7.
Q2 sales €1.52bn; EBITDA €211m aided by cost cuts and a €36.7m pension revaluation; net income includes €243m from Siltronic sale; full‑year guidance adjusted.
Develop bio-based functional ingredients for cosmetics; expand silicone range with renewable raw materials; test novel molecules and production integration.
